PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 129 filers reported holding PROTAGONIST THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 4.22 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,199,509 | -95.0% | 71,913 | -91.7% | 0.00% | -92.3% |
| Q2 2023 | $23,789,769 | +7.9% | 861,324 | -10.2% | 0.01% | +8.3% |
| Q1 2023 | $22,054,493 | +118.4% | 958,891 | +3.6% | 0.01% | +100.0% |
| Q4 2022 | $10,098,972 | +47.5% | 925,662 | +13.9% | 0.01% | +50.0% |
| Q3 2022 | $6,848,000 | +5.9% | 812,355 | -0.7% | 0.00% | 0.0% |
| Q2 2022 | $6,469,000 | -66.8% | 817,832 | -0.5% | 0.00% | -55.6% |
| Q1 2022 | $19,473,000 | -31.0% | 822,323 | -0.3% | 0.01% | -30.8% |
| Q4 2021 | $28,211,000 | +93.4% | 824,872 | +0.2% | 0.01% | +85.7% |
| Q3 2021 | $14,588,000 | -60.4% | 823,290 | +0.2% | 0.01% | -61.1% |
| Q2 2021 | $36,880,000 | +5471.0% | 821,722 | +3114.7% | 0.02% | – |
| Q1 2021 | $662,000 | +30.6% | 25,561 | +1.6% | 0.00% | – |
| Q4 2020 | $507,000 | +58.4% | 25,162 | +53.7% | 0.00% | – |
| Q3 2020 | $320,000 | +56.1% | 16,373 | +41.7% | 0.00% | – |
| Q2 2020 | $205,000 | +376.7% | 11,558 | +88.9% | 0.00% | – |
| Q1 2020 | $43,000 | -78.2% | 6,118 | -78.3% | 0.00% | – |
| Q4 2019 | $197,000 | -18.3% | 28,231 | +39.6% | 0.00% | – |
| Q3 2019 | $241,000 | -56.0% | 20,216 | -55.4% | 0.00% | – |
| Q2 2019 | $548,000 | +36.7% | 45,327 | +41.7% | 0.00% | – |
| Q1 2019 | $401,000 | +40000.0% | 31,994 | +13810.4% | 0.00% | – |
| Q4 2018 | $1,000 | -100.0% | 230 | -99.9% | 0.00% | -100.0% |
| Q3 2018 | $4,161,000 | +5.3% | 404,420 | -31.3% | 0.00% | 0.0% |
| Q2 2018 | $3,953,000 | +2988.3% | 588,380 | +3818.4% | 0.00% | – |
| Q1 2018 | $128,000 | -76.3% | 15,016 | -42.4% | 0.00% | – |
| Q4 2017 | $541,000 | +255.9% | 26,086 | +200.9% | 0.00% | – |
| Q3 2017 | $152,000 | -57.5% | 8,670 | -72.7% | 0.00% | – |
| Q2 2017 | $358,000 | +331.3% | 31,766 | +384.5% | 0.00% | – |
| Q1 2017 | $83,000 | -11.7% | 6,556 | +51.0% | 0.00% | – |
| Q4 2016 | $94,000 | +261.5% | 4,343 | +242.0% | 0.00% | – |
| Q3 2016 | $26,000 | – | 1,270 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $19,373,000 | 4.95% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $17,881,000 | 2.10% |
| Finepoint Capital LP | 735,126 | $5,815,000 | 2.01% |
| Altium Capital Management LP | 365,100 | $2,888,000 | 1.16% |
| RTW INVESTMENTS, LP | 4,794,499 | $37,924,000 | 0.98% |
| Amitell Capital Pte Ltd | 50,129 | $397,000 | 0.90% |
| COWEN AND COMPANY, LLC | 1,065,724 | $8,430,000 | 0.81% |
| Tri Locum Partners LP | 155,000 | $1,226,000 | 0.50% |
| BVF INC/IL | 1,106,838 | $8,755,000 | 0.42% |
| HighVista Strategies LLC | 46,459 | $367,000 | 0.22% |